NGNE
Neurogene
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: NGNE
- PE Ratio
The current PE ratio of NGNE cannot be calculated, as the latest EPS of -$4.56 is negative.
NGNE PE ratio history
Neurogene PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $20.6 | -$4.24 |
| 2024 | N/A | N/A | $22.86 | -$4.28 |
| 2023 | N/A | N/A | $19.38 | -$117.28 |
| 2022 | N/A | N/A | $10.18 | -$139.88 |
| 2021 | N/A | N/A | $96.4 | -$22 |
| 2020 | N/A | N/A | $282 | -$12.8 |
| 2019 | N/A | N/A | $246.4 | -$51 |
| 2018 | N/A | N/A | $43.2 | -$26.8 |
| 2017 | N/A | N/A | $235.2 | -$42.8 |
| 2016 | N/A | N/A | $330.2 | -$39.2 |
| 2015 | N/A | N/A | $249.6 | -$34.6 |
| 2014 | N/A | N/A | $150 | -$55 |
| 2013 | N/A | N/A | N/A | -$990 |
| 2012 | N/A | N/A | N/A | -$805 |
Neurogene PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | N/A | N/A | $20.16 | -$4.56 |
| Dec 2025 | N/A | N/A | $20.6 | -$4.24 |
| Sep 2025 | N/A | N/A | $17.33 | -$4.11 |
| Jun 2025 | N/A | N/A | $14.95 | -$4.31 |
| Mar 2025 | N/A | N/A | $11.71 | -$4.35 |
| Dec 2024 | N/A | N/A | $22.86 | -$4.28 |
| Sep 2024 | N/A | N/A | $41.96 | -$32.9 |
| Jun 2024 | N/A | N/A | $36.39 | -$64.38 |
| Mar 2024 | N/A | N/A | $50.9 | -$89.97 |
| Dec 2023 | N/A | N/A | $19.38 | -$117.28 |
| Sep 2023 | N/A | N/A | $15.8 | -$211.51 |
| Jun 2023 | N/A | N/A | $16.6 | -$183.56 |
| Mar 2023 | N/A | N/A | $14 | -$162.48 |
| Dec 2022 | N/A | N/A | $10.18 | -$139.88 |
| Sep 2022 | N/A | N/A | $12.8 | -$21.32 |
NGNE Price vs fair value
NGNE average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
PE comparison
NGNE PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| VIVS VivoSim Labs Inc. | 0.77 | $3.49M |
| ORMP Oramed Pharmaceuticals Inc | 1.44 | $156.34M |
| OMER Omeros Corp | 7.88 | $741.12M |
| OLMA Olema Pharmaceuticals Inc | N/A | $931.12M |
| ORIC Oric Pharmaceuticals Inc | N/A | $830.21M |
| NGNE Neurogene Inc | N/A | $437.4M |
Frequently asked questions
What is Neurogene's PE ratio?
The current price to earnings ratio of NGNE cannot be determined, as its EPS of -$4.56 is negative.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.